

**Vimta Labs Limited**

Registered Office  
142, IDA Phase II, Cherlapally  
Hyderabad-500 051, Telangana, India  
T : +91 40 2726 4141  
F : +91 40 2726 3657



VLL\SE\012\2025-26  
Date: 28.05.2025

B S E Limited,  
P J Towers, Dalal Street,  
Mumbai: 400001.  
**Scrip Code No.524394**

National Stock Exchange of India Limited,  
"Exchange Plaza", Bandra,  
Kurla Complex, Bandra (E),  
Mumbai – 400051.  
**Trading Symbol: VIMTALABS**

Dear Sir/Madam,

**Sub – Press Release – Audited Financial Results – 31<sup>st</sup> March 2025.**

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the press release regarding the announcement of the Annual Audited Financial Results for the fourth quarter and financial year ended 31<sup>st</sup> March 2025.

This is for your information and records.

Thanking you,

**For VIMTA LABS LIMITED**

**Sujani Vasireddi**  
**Company Secretary**

Encl: as above.





## Vimta Labs Limited Reports Q4 & FY25 Results

**Q4 FY25 Total Income at Rs. 961 Mn, 31.4% YoY**  
**EBITDA margins at 36.1%; PAT margin at 19.1%**  
**Ventures into Biologics Contract R&D services**

**Hyderabad, April 28, 2025: Vimta Labs Limited (VIMTA)** (BSE: 524394, NSE: VIMTALABS), India's leading Contract Research and Testing Organisation, has announced its financial results for the quarter and year ended March 31, 2025.

### Financial Results – Q4 & FY25:

Particulars (Rs. Mn)	Q4 FY25	Q4 FY24	YoY (%)	Q3 FY25	QoQ (%)	FY25	FY24	YoY (%)
Total Income	960.8	731.2	31.4%	911.5	5.4%	3482.2	2923.1	19.1%
EBITDA (including other income)	346.8	263.0	31.9%	343.1	1.1%	1261.9	977.5	29.1%
EBITDA Margin	36.1%	36.0%		37.6%		36.2%	33.4%	
PAT (continued operations)	183.2	139.6	31.2%	175.2	4.6%	667.6	488.1	36.8%
PAT Margin	19.1%	19.1%		19.2%		19.2%	16.7%	
Basic EPS	8.2	6.3	30.1%	7.9	4.6%	30.0	22.0	36.2%

Note: Vimta Labs sold its Diagnostic and Pathological services business to Thyrocare Technologies, as announced on August 30, 2024, with the transfer completed on October 11, 2024. Previous period figures for P&L have been regrouped to ensure comparability with the current period.

### Business Updates:

- Foray into Biologics Contract Research and Development (R&D) services:**

*We are pleased to announce our strategic expansion into Biologics Contract Research and Development services. This foray marks a significant milestone in our growth journey, reinforcing our commitment to serve the evolving needs of the biopharmaceutical industry. The new service line will focus on Novel Biologic Entities (NBEs), biosimilars, and peptide-based therapeutics using both microbial and mammalian platforms. Capabilities will include end-to-end development — from clone and process development to drug product development and biosimilarity assessment. Development lab is being set up, with requisite manpower by Q3 of FY26, and revenues are expected to commence from FY27. This move positions Vimta at the forefront of biologics innovation, expanding our value proposition as a comprehensive, high-quality R&D partner.*



- *The Board of Directors have recommended a final dividend of Rs.2/- (Rupees Two only) per equity share of face value of Rs. 2/- (Rupees Two only) each for the financial year 2024-25 for approval of shareholders in the ensuing AGM.*
- *The Board has recommended the issue of Bonus shares in the ratio of 1:1 subject to the approval of shareholders in the ensuing AGM.*
- *Successful cGMP audit by EMA (European Medicines Agency) for human health products.*
- *Successful GCP regulatory audit by The Ministry of Health of the Republic of Kazakhstan.*
- *Food Division conferred with 'Outstanding Laboratory Performance Award 2024' by CII for the 2nd consecutive year.*
- *EMTAC merger with Vimta: Scheme has been sanctioned by NCLT Hyderabad bench on 23<sup>rd</sup> Jan, 2025.*

**Commenting on results, Ms. Harita Vasireddi, Managing Director, Vimta Labs Limited,** said: *"We are pleased to report strong earnings and good growth this year, driven by growth in pharmaceutical services. Our pharma business benefited from increased traction in clinical and analytical services, supported by capacity expansion and deeper client engagements.*

*Our continued investments in talent, infrastructure, and business development are strengthening our platform for long-term value creation.*

*We are excited to announce our entry into Biologics Contract R&D services, a strategic move that aligns with the future of healthcare and enhances our capabilities across the biopharma value chain. This initiative will enable Vimta to offer end-to-end support for biologics development, reinforcing our position as a trusted partner in high-quality, science-driven innovation.*

*We remain committed to scaling our capabilities, driving innovation, and delivering long-term value for our stakeholders."*

### **Key Result Highlights for the Q4 & FY25 (Consolidated):**

#### **Q4 FY25**

- ✓ Total Income for Q4 FY25 was at Rs. 961 Mn
- ✓ EBITDA for Q4 FY25 was Rs. 347 Mn; EBITDA margin was at 36.1%
- ✓ PBT for Q4 FY25 was at Rs. 250 Mn
- ✓ Q4 FY25 PAT\* was at Rs. 183 Mn; PAT margin was at 19.1%
- ✓ Basic EPS in Q4 FY25 was Rs. 8.2

#### **FY25**

- ✓ Total Income for FY25 was at Rs. 3,482 Mn
- ✓ EBITDA for FY25 was Rs. 1,262 Mn; EBITDA margin was at 36.2%



- ✓ PBT for FY25 was at Rs. 890 Mn
- ✓ FY25 PAT\* was at Rs. 668 Mn; PAT margin was at 19.2%
- ✓ Basic EPS in FY25 was Rs. 30
- ✓ Total Debt as of 31<sup>st</sup> March 2025 stood at Rs. 85 Mn
- ✓ Cash and Cash equivalents including bank balance stood at Rs. 329 Mn as of 31<sup>st</sup> March 2025

Note:

\* Profit/(Loss) for the period from continuing operations

^ Vimta Labs sold its Diagnostic and Pathological services business to Thyrocare Technologies, as announced on August 30, 2024, with the transfer completed on October 11, 2024. Previous period figures for P&L have been regrouped to ensure comparability with the current period

### **ABOUT VIMTA LABS LIMITED:**

Founded in 1984 with headquarters in Hyderabad, India, VIMTA LABS LTD., is a leading contract research and testing organization, providing food, agri, bio/pharmaceutical, medical device, speciality chemical, and electronics companies an integrated scientific, technical, and regulatory expertise to support all stages of product development and manufacturing process. Vimta also provides environmental assessments and testing services.

### **CAUTIONARY STATEMENT:**

*This press release may contain certain forward-looking statements. Any forward-looking statement applies only on the date of this press release. By their nature, forward-looking statements are subject to a number of known and unknown risks and uncertainties that may or may not occur in the future and as a result of which the actual results and performance may differ substantially from the expected future results or performance expressed or implied in the forward-looking statements. No warranties or representations are made as to the accuracy, achievement, or reasonableness of such statements, estimates or projections, and Vimta Labs Limited has no obligation to update any such information or to correct any inaccuracies herein or omission here from which may become apparent.*

### **For details, please contact:**

<b>Investor Relations at Vimta Labs</b> Siva Kambhampati <a href="mailto:Siva.kambhampati@vimta.com">Siva.kambhampati@vimta.com</a> <b>Ernst &amp; Young</b> Mr. Siddesh Chawan <a href="mailto:Siddesh.Chawan@in.ey.com">Siddesh.Chawan@in.ey.com</a> Mr. Advait Bhadekar <a href="mailto:Advait.bhadekar@in.ey.com">Advait.bhadekar@in.ey.com</a>	<b>Registered Office</b> Plot Number 142, IDA Phase 2, Cherlapally, Hyderabad Telangana, India. 500051 CIN: L24110TG1990PLC011977 ISIN: INE579C01029 NSE Code: VIMTALABS BSE CODE: 524394 Website: <a href="http://www.vimta.com">www.vimta.com</a>
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------